A Phase I trial of the farnesyltransferase inhibitor L-778,123 and radiotherapy for locally advanced lung and head and neck cancer.
暂无分享,去创建一个
S. Hahn | J. Tepper | P. Deutsch | D. Haller | R. Muschel | T. Delaney | W. Regine | E. Bernhard | M. Mohiuddin | W. Mckenna | J. Stevenson | Deborah Smith | B. Pramanik | K. D. Kiel | B. Morrison
[1] C. Der,et al. Aberrant function of the Ras signal transduction pathway in human breast cancer , 1995, Breast Cancer Research and Treatment.
[2] M. Morgan,et al. Cell-cycle-dependent activation of mitogen-activated protein kinase kinase (MEK-1/2) in myeloid leukemia cell lines and induction of growth inhibition and apoptosis by inhibitors of RAS signaling. , 2001, Blood.
[3] W. R. Bishop,et al. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines. , 2001, Experimental cell research.
[4] W. Curran,et al. Predictors of severe esophagitis include use of concurrent chemotherapy, but not the length of irradiated esophagus: a multivariate analysis of patients with lung cancer treated with nonoperative therapy. , 2000, International journal of radiation oncology, biology, physics.
[5] R. Muschel,et al. Farnesyltransferase Inhibitors Potentiate the Antitumor Effect of Radiation on a Human Tumor Xenograft Expressing Activated HRAS1 , 2000, Radiation research.
[6] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[7] E K Rowinsky,et al. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] G. Prendergast,et al. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho , 1998, Oncogene.
[9] R. Muschel,et al. Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. , 1998, Cancer research.
[10] M. Leblanc,et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] S. Sebti,et al. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts , 1998, Oncogene.
[12] N. Rosen,et al. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[13] E. Vokes,et al. Phase I study of docetaxel with concomitant thoracic radiation therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] A. Pawson,et al. Proliferation of human malignant astrocytomas is dependent on Ras activation , 1997, Oncogene.
[15] J. Herndon,et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. , 1996, Journal of the National Cancer Institute.
[16] R. Muschel,et al. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts. , 1996, Cancer research.
[17] Dillman Ro. Concurrent chemoradiation in unresectable stage III non-small cell lung cancer: too much pain for no gain. , 1996 .
[18] W. Curran,et al. Long-term survival results for patients with locally advanced, initially unresectable non-small cell lung cancer treated with aggressive concurrent chemoradiation. , 1996, The cancer journal from Scientific American.
[19] R. Muschel,et al. Regulation of radiation-induced apoptosis in oncogene-transfected fibroblasts: influence of H-ras on the G2 delay. , 1996, Oncogene.
[20] C. Der,et al. Overexpression of the Ras-related TC21/R-Ras2 protein may contribute to the development of human breast cancers. , 1996, Oncogene.
[21] P. Casey,et al. Protein prenylation: molecular mechanisms and functional consequences. , 1996, Annual review of biochemistry.
[22] R. Dillman. Concurrent chemoradiation in unresectable stage III non-small cell lung cancer: too much pain for no gain. , 1996, The cancer journal from Scientific American.
[23] G. Prendergast,et al. Evidence that farnesyltransferase inhibitors suppress Ras transformation by interfering with Rho activity , 1995, Molecular and cellular biology.
[24] A. Kral,et al. Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice , 1995, Nature Medicine.
[25] W. Curran,et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. , 1995, Journal of the National Cancer Institute.
[26] 加藤 聖子. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity , 1995 .
[27] A. deFazio,et al. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. , 1994, Oncogene.
[28] C. Ling,et al. Apoptosis induced at different dose rates: implication for the shoulder region of cell survival curves. , 1994, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[29] S. A. Roberts,et al. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. , 1993, British Journal of Cancer.
[30] Y. Tong,et al. Oncogene- transformed NIH 3T3 cells display radiation resistance levels indicative of a signal transduction pathway leading to the radiation-resistant phenotype. , 1993, Radiation research.
[31] A. Levinson,et al. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. , 1993, Science.
[32] D. Samid,et al. Increased radioresistance of ejras‐transformed human osteosarcoma cells and its modulation by lovastatin, an inhibitor of p21ras isoprenylation , 1993, International journal of cancer.
[33] J. Cooper,et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.
[34] H. Bartelink,et al. Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. , 1992, The New England journal of medicine.
[35] J. Miyoshi,et al. Differences in Effects of Oncogenes on Resistance to γ Rays, Ultraviolet Light, and Heat Shock , 1992 .
[36] R. Muschel,et al. Increased G2 delay in radiation-resistant cells obtained by transformation of primary rat embryo cells with the oncogenes H-ras and v-myc. , 1991, Radiation research.
[37] C. Der,et al. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[38] C. Ling,et al. The role of the H-ras oncogene in radiation resistance and metastasis. , 1990, International journal of radiation oncology, biology, physics.
[39] C. Ling,et al. Synergistic effect of the v-myc oncogene with H-ras on radioresistance. , 1990, Cancer research.
[40] J. L. Bos,et al. ras oncogenes in human cancer: a review. , 1989, Cancer research.
[41] W. Blattner,et al. raf involvement in the simultaneous genetic transfer of the radioresistant and transforming phenotypes. , 1989, International journal of radiation biology.
[42] R. Weichselbaum,et al. Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma. , 1989, Science.
[43] M. Sklar. The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation. , 1988, Science.
[44] S. Rockwell,et al. Hypoxic fractions of solid tumors: experimental techniques, methods of analysis, and a survey of existing data. , 1984, International journal of radiation oncology, biology, physics.